|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
53,520,000 |
Market
Cap: |
36.18(M) |
Last
Volume: |
446,593 |
Avg
Vol: |
445,352 |
52
Week Range: |
$0.676 - $0.676 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
375,704 |
572,704 |
572,704 |
572,704 |
Total Buy Value |
$340,817 |
$520,870 |
$520,870 |
$520,870 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
23 |
31 |
31 |
31 |
Total Shares Sold |
0 |
30,110 |
30,110 |
30,110 |
Total Sell Value |
$0 |
$26,460 |
$26,460 |
$26,460 |
Total People Sold |
0 |
2 |
2 |
2 |
Total Sell Transactions |
0 |
5 |
5 |
5 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Boyd Steven |
10% Owner |
|
2018-06-11 |
4 |
B |
$1.18 |
$436,055 |
D/D |
368,705 |
2,668,705 |
2.45 |
- |
|
Boyd Steven |
10% Owner |
|
2018-01-22 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
2,300,000 |
1.42 |
- |
|
Boyd Steven |
10% Owner |
|
2018-01-22 |
4 |
B |
$1.42 |
$143,025 |
D/D |
100,000 |
2,300,000 |
2.45 |
- |
|
Merton Robert C |
Director |
|
2017-11-10 |
4 |
B |
$1.75 |
$149,975 |
D/D |
85,700 |
95,451 |
2.39 |
- |
|
Mammen Mammen |
Sr VP, Clinical DevelopmentOff |
|
2017-05-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,399 |
|
- |
|
Ramos Anthony Alan |
VP, Chief Accounting Officer |
|
2017-03-27 |
4 |
AS |
$2.17 |
$9,240 |
D/D |
(4,250) |
9,674 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2017-03-15 |
4 |
AS |
$2.31 |
$2,021 |
D/D |
(875) |
17,696 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2017-02-01 |
4 |
AS |
$2.16 |
$8,088 |
D/D |
(3,750) |
87,420 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2017-01-11 |
4 |
AS |
$2.48 |
$134 |
D/D |
(54) |
23,071 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2017-01-10 |
4 |
AS |
$2.45 |
$14,114 |
D/D |
(5,763) |
91,170 |
|
- |
|
Merton Robert C |
Director |
|
2016-12-22 |
4 |
S |
$2.26 |
$4,520 |
D/D |
(2,000) |
9,751 |
|
- |
|
Merton Robert C |
Director |
|
2016-12-21 |
4 |
S |
$2.22 |
$4,440 |
D/D |
(2,000) |
11,751 |
|
- |
|
Merton Robert C |
Director |
|
2016-12-20 |
4 |
S |
$2.22 |
$4,440 |
D/D |
(2,000) |
13,751 |
|
- |
|
Merton Robert C |
Director |
|
2016-12-19 |
4 |
S |
$2.21 |
$5,143 |
D/D |
(2,327) |
15,751 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2016-12-13 |
4 |
S |
$2.40 |
$11,172 |
D/D |
(4,649) |
96,933 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2016-12-12 |
4 |
S |
$2.39 |
$26,415 |
D/D |
(11,050) |
101,582 |
|
- |
|
Douglas R Gordon |
Director |
|
2016-12-12 |
4 |
S |
$2.39 |
$24,109 |
D/D |
(10,078) |
10,828 |
|
- |
|
Lyons Gary A |
Director |
|
2016-12-05 |
4 |
S |
$2.30 |
$16,248 |
D/D |
(7,078) |
7,828 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2016-10-11 |
4 |
AS |
$3.05 |
$165 |
D/D |
(54) |
23,125 |
|
- |
|
Anges Mg, Inc. |
|
|
2016-08-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,058,528 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2016-07-11 |
4 |
AS |
$4.46 |
$241 |
D/D |
(54) |
23,179 |
|
- |
|
Merton Robert C |
Director |
|
2016-06-14 |
4 |
B |
$4.41 |
$18,067 |
D/D |
4,100 |
18,078 |
2.39 |
- |
|
Merton Robert C |
Director |
|
2016-06-13 |
4 |
B |
$4.29 |
$21,031 |
D/D |
4,900 |
13,978 |
2.39 |
- |
|
Samant Vijay B |
President & CEO |
|
2016-06-09 |
4 |
B |
$4.72 |
$74,154 |
D/D |
15,700 |
112,632 |
2.81 |
- |
|
Douglas R Gordon |
Director |
|
2016-06-06 |
4 |
B |
$4.41 |
$44,444 |
D/D |
10,078 |
20,906 |
2.39 |
- |
|
258 Records found
|
|
Page 8 of 11 |
|
|